{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:07:59Z","timestamp":1773122879089,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of the present study was to assess whether 6-week ranolazine application on top of guideline-based treatment impacts on the arginine\/NO pathway and urinary isoprostane 8-iso-PGF<jats:sub>2\u03b1<\/jats:sub> as marker of oxidative stress in patients directly after a myocardial infarction. 20 patients with unstable angina pectoris and proof of acute cardiac ischemia entered the study. 10 subjects received the study drug ranolazine in addition to standard treatment, the others received only standard treatment. Urine and venous blood were collected before and after treatment. At the end of the study and compared to baseline, homoarginine levels had increased in the control group. This was not the case in ranolazine-patients. Interestingly, in ranolazine-treated-patients arginine plasma levels were significantly higher at the end of the study than at baseline (difference +26 \u00b5mol\/L, 95% CI 8.6 to 44 \u00b5mol\/L). ADMA and SDMA levels were not different. Urine levels of the oxidative stress marker 8-iso-PGF<jats:sub>2\u03b1<\/jats:sub> tended to be lower in ranolazine-treated patients (\u2212144 pmol\/mg creatinine). Findings of this hypothesis-driven study give evidence that ranolazine treatment enhances arginine plasma levels and lowers oxidative stress.<\/jats:p>","DOI":"10.1038\/s41598-019-42239-1","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:02:56Z","timestamp":1554458576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of ranolazine on plasma arginine derivatives and urinary isoprostane 8-iso-PGF2\u03b1 in patients with myocardial infarction in the randomized RIMINI-Trial"],"prefix":"10.1038","volume":"9","author":[{"given":"Tjark F.","family":"Schwemer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navina","family":"Deutscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Diermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"B\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edzard","family":"Schwedhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Blankenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-9445","authenticated-orcid":false,"given":"Felix W.","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"42239_CR1","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","volume":"349","author":"CJ Murray","year":"1997","unstructured":"Murray, C. J. & Lopez, A. D. Alternative projections of mortality and disability by cause 1990\u20132020: Global Burden of Disease Study. Lancet 349, 1498\u20131504, https:\/\/doi.org\/10.1016\/S0140-6736(96)07492-2 (1997).","journal-title":"Lancet"},{"key":"42239_CR2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.rec.2015.10.009","volume":"68","author":"M Roffi","year":"2015","unstructured":"Roffi, M. et al. ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista espanola de cardiologia 68, 1125, https:\/\/doi.org\/10.1016\/j.rec.2015.10.009 (2015).","journal-title":"Revista espanola de cardiologia"},{"key":"42239_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1006\/niox.2001.0394","volume":"6","author":"AJ Maxwell","year":"2002","unstructured":"Maxwell, A. J. Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric oxide: biology and chemistry 6, 101\u2013124, https:\/\/doi.org\/10.1006\/niox.2001.0394 (2002).","journal-title":"Nitric oxide: biology and chemistry"},{"key":"42239_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/157340310791162659","volume":"6","author":"L Sibal","year":"2010","unstructured":"Sibal, L., Agarwal, S. C., Home, P. D. & Boger, R. H. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Current cardiology reviews 6, 82\u201390, https:\/\/doi.org\/10.2174\/157340310791162659 (2010).","journal-title":"Current cardiology reviews"},{"key":"42239_CR5","first-page":"739","volume":"218","author":"LJ Ignarro","year":"1981","unstructured":"Ignarro, L. J. et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. The Journal of pharmacology and experimental therapeutics 218, 739\u2013749 (1981).","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"42239_CR6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/CIRCRESAHA.107.165779","volume":"101","author":"HK Surks","year":"2007","unstructured":"Surks, H. K. cGMP-dependent protein kinase I and smooth muscle relaxation: a tale of two isoforms. Circulation research 101, 1078\u20131080, https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.165779 (2007).","journal-title":"Circulation research"},{"key":"42239_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJM199007053230105","volume":"323","author":"JA Panza","year":"1990","unstructured":"Panza, J. A., Quyyumi, A. A., Brush, J. E. Jr. & Epstein, S. E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. The New England journal of medicine 323, 22\u201327, https:\/\/doi.org\/10.1056\/NEJM199007053230105 (1990).","journal-title":"The New England journal of medicine"},{"key":"42239_CR8","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1161\/01.CIR.98.18.1842","volume":"98","author":"RH Boger","year":"1998","unstructured":"Boger, R. H. et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98, 1842\u20131847 (1998).","journal-title":"Circulation"},{"key":"42239_CR9","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1161\/01.CIR.88.5.2149","volume":"88","author":"DS Celermajer","year":"1993","unstructured":"Celermajer, D. S. et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88, 2149\u20132155 (1993).","journal-title":"Circulation"},{"key":"42239_CR10","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1093\/eurheartj\/ehs100","volume":"34","author":"M Oelze","year":"2013","unstructured":"Oelze, M. et al. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. European heart journal 34, 3206\u20133216, https:\/\/doi.org\/10.1093\/eurheartj\/ehs100 (2013).","journal-title":"European heart journal"},{"key":"42239_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jama.295.1.58","volume":"295","author":"SP Schulman","year":"2006","unstructured":"Schulman, S. P. et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. Jama 295, 58\u201364, https:\/\/doi.org\/10.1001\/jama.295.1.58 (2006).","journal-title":"Jama"},{"key":"42239_CR12","doi-asserted-by":"crossref","unstructured":"Blum, A. et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. The American journal of cardiology 83, 1488-1490, A1488 (1999).","DOI":"10.1016\/S0002-9149(99)00129-0"},{"key":"42239_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0002-9149(97)00354-8","volume":"80","author":"L Ceremuzynski","year":"1997","unstructured":"Ceremuzynski, L., Chamiec, T. & Herbaczynska-Cedro, K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. The American journal of cardiology 80, 331\u2013333 (1997).","journal-title":"The American journal of cardiology"},{"key":"42239_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0735-1097(01)01380-8","volume":"38","author":"HA Walker","year":"2001","unstructured":"Walker, H. A. et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine\/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. Journal of the American College of Cardiology 38, 499\u2013505 (2001).","journal-title":"Journal of the American College of Cardiology"},{"key":"42239_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/eurjhf\/hfq158","volume":"12","author":"M Visser","year":"2010","unstructured":"Visser, M. et al. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. European journal of heart failure 12, 1274\u20131281, https:\/\/doi.org\/10.1093\/eurjhf\/hfq158 (2010).","journal-title":"European journal of heart failure"},{"key":"42239_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1161\/01.ATV.0000128897.54893.26","volume":"24","author":"P Vallance","year":"2004","unstructured":"Vallance, P. & Leiper, J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arteriosclerosis, thrombosis, and vascular biology 24, 1023\u20131030, https:\/\/doi.org\/10.1161\/01.ATV.0000128897.54893.26 (2004).","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"key":"42239_CR17","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/01.RES.0000181286.44222.61","volume":"97","author":"R Schnabel","year":"2005","unstructured":"Schnabel, R. et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circulation research 97, e53\u201359, https:\/\/doi.org\/10.1161\/01.RES.0000181286.44222.61 (2005).","journal-title":"Circulation research"},{"key":"42239_CR18","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.108.838268","volume":"119","author":"RH Boger","year":"2009","unstructured":"Boger, R. H. et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119, 1592\u20131600, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.838268 (2009).","journal-title":"Circulation"},{"key":"42239_CR19","doi-asserted-by":"publisher","first-page":"e002565","DOI":"10.1161\/JAHA.115.002565","volume":"5","author":"D Atzler","year":"2016","unstructured":"Atzler, D. et al. Low Homoarginine Levels in the Prognosis of Patients With Acute Chest Pain. Journal of the American Heart Association 5, e002565, https:\/\/doi.org\/10.1161\/JAHA.115.002565 (2016).","journal-title":"Journal of the American Heart Association"},{"key":"42239_CR20","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","volume":"297","author":"DA Morrow","year":"2007","unstructured":"Morrow, D. A. et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. Jama 297, 1775\u20131783, https:\/\/doi.org\/10.1001\/jama.297.16.1775 (2007).","journal-title":"Jama"},{"key":"42239_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jcmg.2009.09.006","volume":"2","author":"R Venkataraman","year":"2009","unstructured":"Venkataraman, R., Belardinelli, L., Blackburn, B., Heo, J. & Iskandrian, A. E. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC. Cardiovascular imaging 2, 1301\u20131309, https:\/\/doi.org\/10.1016\/j.jcmg.2009.09.006 (2009).","journal-title":"JACC. Cardiovascular imaging"},{"key":"42239_CR22","doi-asserted-by":"publisher","first-page":"107424841878429","DOI":"10.1177\/1074248418784290","volume":"0","author":"TF Schwemer","year":"2018","unstructured":"Schwemer, T. F. et al. Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial. Journal of cardiovascular pharmacology and therapeutics 0, 1074248418784290, https:\/\/doi.org\/10.1177\/1074248418784290 (2018).","journal-title":"Journal of cardiovascular pharmacology and therapeutics"},{"key":"42239_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.arcmed.2012.11.002","volume":"44","author":"MC Paredes-Carbajal","year":"2013","unstructured":"Paredes-Carbajal, M. C. et al. Effects of ranolazine on vasomotor responses of rat aortic rings. Archives of medical research 44, 8\u201312, https:\/\/doi.org\/10.1016\/j.arcmed.2012.11.002 (2013).","journal-title":"Archives of medical research"},{"key":"42239_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0008-6363(00)00118-8","volume":"47","author":"A Mezzetti","year":"2000","unstructured":"Mezzetti, A., Cipollone, F. & Cuccurullo, F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovascular research 47, 475\u2013488 (2000).","journal-title":"Cardiovascular research"},{"key":"42239_CR25","doi-asserted-by":"crossref","unstructured":"Lim, P. S. et al. 8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients. Blood purification 20, 537\u2013542, doi:66962 (2002).","DOI":"10.1159\/000066962"},{"key":"42239_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/01.CIR.0000116761.93647.30","volume":"109","author":"E Schwedhelm","year":"2004","unstructured":"Schwedhelm, E. et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 109, 843\u2013848, https:\/\/doi.org\/10.1161\/01.CIR.0000116761.93647.30 (2004).","journal-title":"Circulation"},{"key":"42239_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/01.mca.0000063504.13456.c3","volume":"14","author":"C Vassalle","year":"2003","unstructured":"Vassalle, C., Botto, N., Andreassi, M. G., Berti, S. & Biagini, A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coronary artery disease 14, 213\u2013218, https:\/\/doi.org\/10.1097\/01.mca.0000063504.13456.c3 (2003).","journal-title":"Coronary artery disease"},{"key":"42239_CR28","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/j.jchromb.2011.06.016","volume":"879","author":"D Atzler","year":"2011","unstructured":"Atzler, D., Mieth, M., Maas, R., Boger, R. H. & Schwedhelm, E. Stable isotope dilution assay for liquid chromatography-tandem mass spectrometric determination of L-homoarginine in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 879, 2294\u20132298, https:\/\/doi.org\/10.1016\/j.jchromb.2011.06.016 (2011).","journal-title":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"key":"42239_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jchromb.2006.11.052","volume":"851","author":"E Schwedhelm","year":"2007","unstructured":"Schwedhelm, E. et al. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 851, 211\u2013219, https:\/\/doi.org\/10.1016\/j.jchromb.2006.11.052 (2007).","journal-title":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"key":"42239_CR30","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1161\/ATVBAHA.113.301219","volume":"33","author":"MO Gore","year":"2013","unstructured":"Gore, M. O. et al. Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study. Arteriosclerosis, thrombosis, and vascular biology 33, 2682\u20132688, https:\/\/doi.org\/10.1161\/ATVBAHA.113.301219 (2013).","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"key":"42239_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1570-0232(03)00457-4","volume":"794","author":"D Tsikas","year":"2003","unstructured":"Tsikas, D. et al. Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications. J Chromatogr B Analyt Technol Biomed Life Sci 794, 237\u2013255 (2003).","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"42239_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0378-4347(00)00236-X","volume":"744","author":"E Schwedhelm","year":"2000","unstructured":"Schwedhelm, E. et al. Tandem mass spectrometric quantification of 8-iso-prostaglandin F2alpha and its metabolite 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2alpha in human urine. Journal of chromatography. B, Biomedical sciences and applications 744, 99\u2013112 (2000).","journal-title":"Journal of chromatography. B, Biomedical sciences and applications"},{"key":"42239_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1046\/j.1365-2125.1999.00883.x","volume":"47","author":"O Tangphao","year":"1999","unstructured":"Tangphao, O., Grossmann, M., Chalon, S., Hoffman, B. B. & Blaschke, T. F. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. British journal of clinical pharmacology 47, 261\u2013266 (1999).","journal-title":"British journal of clinical pharmacology"},{"key":"42239_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1476-5381.1992.tb14365.x","volume":"106","author":"A Wennmalm","year":"1992","unstructured":"Wennmalm, A., Benthin, G. & Petersson, A. S. Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. British journal of pharmacology 106, 507\u2013508 (1992).","journal-title":"British journal of pharmacology"},{"key":"42239_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1042\/cs0820631","volume":"82","author":"H Suzuki","year":"1992","unstructured":"Suzuki, H. et al. Increases in NO2-\/NO3- excretion in the urine as an indicator of the release of endothelium-derived relaxing factor during elevation of blood pressure. Clinical science 82, 631\u2013634 (1992).","journal-title":"Clinical science"},{"key":"42239_CR36","doi-asserted-by":"publisher","first-page":"E884","DOI":"10.1152\/ajpcell.1995.269.4.C884","volume":"269","author":"L Beaumier","year":"1995","unstructured":"Beaumier, L., Castillo, L., Ajami, A. M. & Young, V. R. Urea cycle intermediate kinetics and nitrate excretion at normal and \u201ctherapeutic\u201d intakes of arginine in humans. The American journal of physiology 269, E884\u2013896 (1995).","journal-title":"The American journal of physiology"},{"key":"42239_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22099-x","volume":"8","author":"S Tommasi","year":"2018","unstructured":"Tommasi, S. et al. Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance. Sci Rep 8, 3697, https:\/\/doi.org\/10.1038\/s41598-018-22099-x (2018).","journal-title":"Sci Rep"},{"key":"42239_CR38","doi-asserted-by":"publisher","first-page":"9383","DOI":"10.1073\/pnas.87.23.9383","volume":"87","author":"JD Morrow","year":"1990","unstructured":"Morrow, J. D. et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America 87, 9383\u20139387 (1990).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"42239_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0163-7827(97)00001-5","volume":"36","author":"JD Morrow","year":"1997","unstructured":"Morrow, J. D. & Roberts, L. J. The isoprostanes: unique bioactive products of lipid peroxidation. Progress in lipid research 36, 1\u201321 (1997).","journal-title":"Progress in lipid research"},{"key":"42239_CR40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1365-2796.2004.01373.x","volume":"256","author":"C Vassalle","year":"2004","unstructured":"Vassalle, C., Petrozzi, L., Botto, N., Andreassi, M. G. & Zucchelli, G. C. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. Journal of internal medicine 256, 308\u2013315, https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01373.x (2004).","journal-title":"Journal of internal medicine"},{"key":"42239_CR41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1582-4934.2002.tb00456.x","volume":"6","author":"S Clejan","year":"2002","unstructured":"Clejan, S. et al. Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis. Journal of cellular and molecular medicine 6, 583\u2013592 (2002).","journal-title":"Journal of cellular and molecular medicine"},{"key":"42239_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0002-8703(99)70163-8","volume":"138","author":"Y Nakamura","year":"1999","unstructured":"Nakamura, Y., Moss, A. J., Brown, M. W., Kinoshita, M. & Kawai, C. Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. American heart journal 138, 577\u2013585 (1999).","journal-title":"American heart journal"},{"key":"42239_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1172\/JCI3985","volume":"103","author":"Z Mallat","year":"1999","unstructured":"Mallat, Z. et al. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. The Journal of clinical investigation 103, 421\u2013427, https:\/\/doi.org\/10.1172\/JCI3985 (1999).","journal-title":"The Journal of clinical investigation"},{"key":"42239_CR44","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1161\/CIRCULATIONAHA105.562223","volume":"112","author":"M Tang","year":"2005","unstructured":"Tang, M., Cyrus, T., Yao, Y., Vocun, L. & Pratico, D. Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 112, 2867\u20132874, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA105.562223 (2005).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42239-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:31:38Z","timestamp":1671265898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42239-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42239"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42239-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"22 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5708"}}